One of the main challenges in targeting ATF6 is its role in normal cellular functions. ATF6 is essential for maintaining ER homeostasis in healthy cells, so systemic inhibition could lead to unwanted side effects. Therefore, therapeutic strategies must be carefully designed to selectively target cancer cells without disrupting normal cellular processes.
